Drug Profile


Alternative Names: R-850; S-30594

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 3M Pharmaceuticals
  • Developer Meda
  • Class Antineoplastics; Naphthyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Actinic keratosis

Most Recent Events

  • 21 Jul 2015 No recent reports on development identified - Phase-II for Actinic keratosis in Europe (Topical)
  • 17 Aug 2012 Phase II development is ongoing in the European Union
  • 31 Dec 2009 Phase-II clinical trials in Actinic keratosis in Europe (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top